X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (26) 26
female (20) 20
index medicus (20) 20
male (20) 20
middle aged (18) 18
aged (15) 15
adult (12) 12
copd (12) 12
mortality (12) 12
respiratory system (12) 12
chronic obstructive pulmonary disease (9) 9
lung diseases, obstructive (9) 9
androstadienes - administration & dosage (8) 8
double-blind method (8) 8
obstructive pulmonary-disease (8) 8
pulmonary disease, chronic obstructive - physiopathology (8) 8
administration, inhalation (7) 7
asthma (7) 7
asthma - drug therapy (7) 7
bronchodilator agents - administration & dosage (7) 7
pulmonary disease, chronic obstructive - complications (7) 7
treatment outcome (7) 7
aged, 80 and over (6) 6
androstadienes - adverse effects (6) 6
cardiovascular disease (6) 6
medical research (6) 6
medicine, experimental (6) 6
prognosis (6) 6
pulmonary disease, chronic obstructive - diagnosis (6) 6
pulmonary disease, chronic obstructive - drug therapy (6) 6
risk factors (6) 6
abridged index medicus (5) 5
allergy (5) 5
benzyl alcohols - administration & dosage (5) 5
bronchodilator agents - adverse effects (5) 5
chlorobenzenes - administration & dosage (5) 5
clinical trials (5) 5
drug administration schedule (5) 5
drug combinations (5) 5
fluticasone (5) 5
internal medicine (5) 5
longitudinal studies (5) 5
pulmonary disease, chronic obstructive - mortality (5) 5
research (5) 5
risk (5) 5
adolescent (4) 4
benzyl alcohols - adverse effects (4) 4
biomarkers - blood (4) 4
chlorobenzenes - adverse effects (4) 4
critical care medicine (4) 4
dose-response relationship, drug (4) 4
fluticasone furoate (4) 4
immunology (4) 4
lung-function (4) 4
patients (4) 4
prospective studies (4) 4
pulmonary disease, chronic obstructive - psychology (4) 4
respiratory agents (4) 4
salmeterol (4) 4
severity of illness index (4) 4
studies (4) 4
vilanterol (4) 4
air-flow obstruction (3) 3
association (3) 3
biomarkers (3) 3
bronchodilator agents - therapeutic use (3) 3
cardiovascular diseases (3) 3
child (3) 3
cohort (3) 3
corticosteroids (3) 3
disease (3) 3
disease progression (3) 3
drug therapy (3) 3
dyspnea (3) 3
events (3) 3
forced expiratory volume (3) 3
forced expiratory volume - drug effects (3) 3
furoate (3) 3
glucocorticoids - administration & dosage (3) 3
glucocorticoids - adverse effects (3) 3
heart attacks (3) 3
hospitalization (3) 3
lung - physiopathology (3) 3
lung diseases (3) 3
management (3) 3
medicine (3) 3
medicine, general & internal (3) 3
metered dose inhalers (3) 3
moderate (3) 3
outcomes (3) 3
population (3) 3
pulmonary/respiratory (3) 3
respiratory function tests (3) 3
risk assessment (3) 3
surveys and questionnaires (3) 3
time factors (3) 3
united states (3) 3
adults (2) 2
aerosol (2) 2
african americans - statistics & numerical data (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 2, pp. 129 - 136
Journal Article
Journal of the American Medical Directors Association, ISSN 1525-8610, 2012, Volume 13, Issue 3, pp. 291 - 297
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 3, pp. 210 - 223
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2012, Volume 34, Issue 8, pp. 1655 - 1666.e5
Abstract Background Available inhaled corticosteroid/long-acting β2 -agonist combinations for chronic obstructive pulmonary disease (COPD) require twice-daily... 
Internal Medicine | Medical Education | fluticasone furoate | vilanterol | efficacy | COPD | once-daily | Vilanterol | Efficacy | Once-daily | Fluticasone furoate | MODERATE | SAFETY | PERSISTENT ASTHMA | FUROATE | SALMETEROL | PROPIONATE | FORMOTEROL | INHALED BUDESONIDE | THERAPY | PHARMACOLOGY & PHARMACY | Spirometry | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | United States | Humans | Middle Aged | Benzyl Alcohols - administration & dosage | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Chlorobenzenes - administration & dosage | Forced Expiratory Volume | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Female | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Powders | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Cross-Over Studies | Vital Capacity | Androstadienes - administration & dosage | Chlorobenzenes - adverse effects | Lung - drug effects | Aerosols | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Androstadienes - adverse effects | Drug Combinations | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Medical research | Care and treatment | Corticosteroids | Medicine, Experimental | Respiratory agents | Asthma | Patient safety | Disease | Medical treatment | Quality control
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 142, Issue 1, pp. 119 - 127
Background Vilanterol (GW642444M) (VI) is a novel, inhaled, long-acting β2 agonist with inherent 24-h activity under development as a once-daily combination... 
Pulmonary/Respiratory
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 09/2018, Volume 72, Issue 10, pp. 1126 - 1137
Journal Article
Human Molecular Genetics, ISSN 0964-6906, 01/2012, Volume 21, Issue 4, pp. 947 - 957
Journal Article
International Journal of COPD, ISSN 1176-9106, 12/2015, Volume 11, pp. 1 - 12
Background: Fluticasone furoate/vilanterol (FF/VI) is a novel, once-daily, inhaled corticosteroid/long-acting beta(2)-agonist combination approved for the... 
Tiotropium | Cardiovascular disease | ICS/LABA | Fluticasone furoate/vilanterol | Anticholinergic | COPD | VILANTEROL | MORTALITY | cardiovascular disease | EVENTS | MU-G | LUNG-FUNCTION | anticholinergic | FUROATE | tiotropium | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | ARTERIAL STIFFNESS | fluticasone furoate/vilanterol | CONTROLLER THERAPY | CLINICALLY IMPORTANT DIFFERENCE | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Benzyl Alcohols - administration & dosage | Benzyl Alcohols - adverse effects | Male | Symptom Assessment - methods | Pulmonary Disease, Chronic Obstructive - physiopathology | Drug Monitoring - methods | Chlorobenzenes - administration & dosage | Cardiovascular Diseases - complications | Tiotropium Bromide - administration & dosage | Adult | Female | Bronchodilator Agents - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Tiotropium Bromide - adverse effects | Administration, Inhalation | Treatment Outcome | Pulmonary Disease, Chronic Obstructive - complications | Androstadienes - administration & dosage | Chlorobenzenes - adverse effects | Pulmonary Disease, Chronic Obstructive - psychology | Quality of Life | Aged | Androstadienes - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article